1492 Capital Management’s Intellia Therapeutics NTLA Stock Holding History

1492 Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,164	Closed	-$455K	–	104
2023 Q2	$455K	Sell	11,164 -5	-0%	-$203	0.27%	73
2023 Q1	$416K	Sell	11,169 -4	-0%	-$157	0.26%	74
2022 Q4	$390K	Hold	11,173	–	–	0.25%	77
2022 Q3	$625K	Buy	11,173 +217	+2%	+$13.5K	0.45%	72
2022 Q2	$567K	Buy	+10,956	New	+$556K	0.37%	76

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

1492 Capital Management's NTLA Position: Q3 2023 in Review

1492 Capital Management sold out of Intellia Therapeutics (NTLA) in Q3 2023, closing a stake of 11,164 shares — an estimated $455K sold.

1492 Capital Management first reported a position in NTLA in Q2 2022 and held it in 5 quarters. The position peaked at $625K in Q3 2022. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

1492 Capital Management reported no remaining Intellia Therapeutics position as of Q3 2023 after selling out during the quarter.
1492 Capital Management sold 11,164 Intellia Therapeutics shares in Q3 2023, an estimated $455K.
1492 Capital Management first reported a position in Intellia Therapeutics in Q2 2022 and held it in 5 quarters.
1492 Capital Management's Intellia Therapeutics position peaked at $625K in Q3 2022.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on 1492 Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.